- Topic
31k Popularity
15k Popularity
59k Popularity
3k Popularity
8k Popularity
5k Popularity
10k Popularity
46k Popularity
151k Popularity
- Pin
- GT Airdrop Is Live! 1.92M GT Burned in Q2, Worth Over $39M
🎁 Complete simple tasks, get up to 13.2 GT per user
📅 From July 8 to July 20
👉 Join now + trade futures to qualify: https://www.gate.com/campaigns/1431
- 📢 #Gate Square Writing Contest Phase 1# is now officially launched!
Share your unique insights on the CROSS project and stand a chance to win $500 worth of CROSS rewards!
💰 Rewards:
1st Prize (1 winner): $150 worth of CROSS
2nd Prize (3 winners): $50 worth of CROSS each
3rd Prize (10 winners): $20 worth of CROSS each
👉 How to Participate:
1. Publish your unique insights on the CROSS project in Gate Square.
2. Add the tag #Gate Square Writing Contest Phase 1# to your post (minimum of 300 words).
3. Share your article or insights on X with the tags: Gate Square & CROSS.
Essay Content Directio
- 🎉 #Gate xStocks Trading Share# Posting Event Is Ongoing!
📝 Share your trading experience on Gate Square to unlock $1,000 rewards!
🎁 5 top Square creators * $100 Futures Voucher
🎉 Share your post on X – Top 10 posts by views * extra $50
How to Participate:
1️⃣ Follow Gate_Square
2️⃣ Make an original post (at least 20 words) with #Gate xStocks Trading Share#
3️⃣ If you share on Twitter, submit post link here: https://www.gate.com/questionnaire/6854
Note: You may submit the form multiple times. More posts, higher chances to win!
📅 End at: July 9, 16:00 UTC
Show off your trading on Gate Squ
- 🚀 Calling all Gate Square content creators!
Join the Gate 2025 Mid-Year Gala to become a top creator
Win Gate x Red Bull merch, $1,000 Futures Vouchers, VIP+1, and fan-exclusive rewards!
Sign up now 👉 www.gate.com/activities/community-vote
#GateSquare#
Global Real-World Study Results of the Largest-scale JAK1 Inhibitor Released
On March 8th, Jinshi Data reported that at the recent AAD meeting in the United States, the interim results of the world's largest JAK1 inhibitor, Abrocitinib, in the real world study AHEAD (Abrocitinib CHinese rEgistry on AD) were internationally released. This provides more real-world research and medical evidence data for the innovative small molecule drug with high selectivity JAK1 inhibitor in the field of atopic dermatitis (AD), further strengthening the clinical scientific basis to optimize treatment strategies and drive the reshaping of AD diagnosis and treatment pathways.